Cited by 199Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.

GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia

Open access

Lanctôt, Krista L, Herrmann, Nathan, Mazzotta, Paolo, Khan, Lyla R, Ingber, Neil·2004·The Canadian Journal of Psychiatry

DOI 10.1177/070674370404900705

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer's disease (AD) is characterized by disruptions in multiple major neurotransmitters. While many studies have attempted to establish whether GABA is disrupted in AD patients, findings have varied. We review evidence for disruptions in GABA among patients with AD and suggest that the variable findings reflect subtypes of the disease that are possibly manifested clinically by differing behavioural symptoms. GABA, the major inhibitory neurotransmitter, has long been a target for anxiolytics, hypnotic sedatives, and anticonvulsants. We review the clinical use of GABAergic agents in treating persons with AD symptoms. While newer generation GABAergic medications are now available, they have yet to be evaluated among patients with AD.

Integrity signals

Registry

Crossref · 10.1177/070674370404900705

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Psychopharmacology: The third generation of progress
O’Connell, R. A. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90057-0 · Cited by 3,020
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.
Perry, E., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P., & Perry, R. H. (1978) · British medical journal · doi:10.1136/bmj.2.6150.1457 · Cited by 2,043
Psychopharmacology: The Third Generation of Progress.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,021
The Biochemical Basis of Neuropharmacology.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-575_2 · Cited by 1,882
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
Small, G. W. (1997) · JAMA · doi:10.1001/jama.1997.03550160083043 · Cited by 992
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634

Flagged first, then by citations

Show all 146 references

Research works printed but not linked: 22

Canadian Study of Health and Aging Working Group, 1994, Can Med Assoc J, 150, 899
Malick JB, 1970, Arch Int Pharmacodyn Ther, 184, 252
Delgado JMR, 1973, Antiaggressive effects of chlordiazepoxide
Sedvall G, 1987, J Neural Transm Suppl, 24, 43
Sherif F, 1995, Neurodegeneration, 4, 114
Fukuchi K, 1997, J Nucl Med, 38, 467
Wyper D, 1998, Inter J Geriatr Psychopharmacol, 1, 126
Oishi M, 1996, Ann Clin Lab Sci, 26, 340
Kuroda H., 1983, Acta Med Okayama, 37, 167
Bareggi SR, 1982, Age or disease-related modifications? Arch Neurol, 39, 709
Freinhar JP, 1986, J Clin Psychiatry, 47, 525
Fritz J, 1990, Am J Psychiatry, 147
Sanders JF, 1965, Geriatrics, 20, 739
Beber CR, 1965, Dis Nerv Syst, 26, 591
Chesrow EJ, 1965, Clin Med, 71, 1001
Herz LR, 1992, Hosp Community Psychiatry, 43, 720
Marin DB, 1989, Am J Psychiatry, 146
Lemke MR, 1995, J Clin Psychiatry, 56, 354
Gleason RP, 1990, J Clin Psychiatry, 51, 115
Gupta S, 1998, Int J Geriatr Psychopharmacol, 1, 244
Fahs H, 1999, Encephale, 25, 169
Horne M, 1995, J Clin Psychiatry, 56, 430

Sorted by citations

Items 101–199 of 199

Ghrelin Causes a Decline in GABA Release by Reducing Fatty Acid Oxidation in Cortex
Mir, J. F., Zagmutt, S., Lichtenstein, M. P., García‐Villoria, J., Weber, M., Gracia, A., Fabriàs, G., Casas, J., López, M., Casals, N., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0921-3 · Cited by 24
“It activates itself in pathological events such as Alzheimer’s disease [74], epileptic episodes [75, 76], and after brain ischemia [77, 78].”
Background
Two component hydrogel with γ-amino butyric acid as potential receptor and neurotransmitter delivery system
Haldar, D. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.10.074 · Cited by 22
Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer’s Disease
Karim, S., Mirza, Z., Ansari, S. A., Rasool, M., Iqbal, Z., Sohrab, S. S., Kamal, M. A., Abuzenadah, A. M., & Al-Qahtani, M. H. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917113446 · Cited by 21
Pathology of nNOS-Expressing GABAergic Neurons in Mouse Model of Alzheimer’s Disease
Choi, S., Won, J., Carroll, S. L., Annamalai, B., Singh, I., & Singh, A. K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.05.013 · Cited by 23
Gut instincts: Unveiling the connection between gut microbiota and Alzheimer's disease
Peddinti, V., Avaghade, M. M., Suthar, S. U., Rout, B., Gomte, S. S., Agnihotri, T. G., & Jain, A. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.02.019 · Cited by 24
Anterior Insula GABA Levels Correlate with Emotional Aspects of Empathy: A Proton Magnetic Resonance Spectroscopy Study
Wang, Q., Zhang, Z., Dong, F., Chen, L., Zheng, L., Guo, X., & Li, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113845 · Cited by 21
“The GABA system is the major inhibitory system in the human brain [13].”
Background
Propofol and Thiopental Suppress Amyloid Fibril Formation and GM1 Ganglioside Expression through the γ-Aminobutyric Acid A Receptor
Yamamoto, N., Arima, H., Sugiura, T., Hirate, H., Taniura, H., Suzuki, K., & Sobue, K. (2013) · Anesthesiology · doi:10.1097/aln.0b013e31828afc16 · Cited by 21
Phenelzine: An Old Drug That May Hold Clues to The Development of New Neuroprotective Agents
MacKenzie, E. M., Song, M.-S., Dursun, S. M., Tomlinson, S. E., Todd, K. G., & Baker, G. B. (2010) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2010.11790656 · Cited by 21
“It is also interesting to note that glutamate-associated excitotoxicity is also thought to play a role in the neurodegeneration observed in Alzheimer’s disease (4850) and GABAergic deficits have been reported in AD, although these latter findings are conflicting and complicated by variables such as illness severity an…”
Background
Neurotransmitter depletion may be a cause of dementia pathology rather than an effect
Alisky, J. M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.02.043 · Cited by 21
“[5] Lanctot KL, Herrmann N, Mazzotta P, et al.”
Background
Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample
Ramos‐Miguel, A., Jones, A. A., Petyuk, V., Barakauskas, V., Barr, A. M., Leurgans, S. E., Jager, P. L. D., Casaletto, K. B., Schneider, J. A., Bennett, D. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02282-7 · Cited by 20
The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases
Ghosh, I., Liu, C. S., Swardfager, W., Lanctôt, K. L., & Anderson, N. D. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103683 · Cited by 20
Self-citation
The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer’s Disease
Wang, Y. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220417005115 · Cited by 21
Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies
Richardson, K., Savva, G. M., Boyd, P. J., Aldus, C. F., Maidment, I., Pakpahan, E., Loke, Y. K., Arthur, A. J., Steel, N., Ballard, C. G., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25010 · Cited by 21
Framing Neuro-Glia Coupling in Antiepileptic Drug Design
Kardos, J., Szabó, Z. M., & Héja, L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00331 · Cited by 19
Increase in cortical endocannabinoid signaling in a rat model of basal forebrain cholinergic dysfunction
Llorente‐Ovejero, A., Manuel, I., Giralt, M. T., & Rodríguez‐Puertas, R. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.008 · Cited by 19
“Finally, recovery of the cortical GABAergic tone has been postulated as potentially therapeutic in AD patients (see review in Lanctôt et al., 2004).”
Background
SPECT imaging of GABAA/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment
Pappatà, S., Varrone, A., Vicidomini, C., Milan, G., Falco, C. D., Sansone, V., Iavarone, A., Comerci, M., Loré, E., Panico, M., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1409-1 · Cited by 18
Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor
Yamamoto, N., Arima, H., Sugiura, T., Hirate, H., Kusama, N., Suzuki, K., & Sobue, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.022 · Cited by 18
A review on gut microbiota and miRNA crosstalk: implications for Alzheimer’s disease
Ayyanar, M. P., & Vijayan, M. (2024) · GeroScience · doi:10.1007/s11357-024-01432-5 · Cited by 22
“Postmortem examinations of cortical areas in AD patients have shown decreased GABA concentrations in the frontal, temporal, and parietal regions [58].”
Multicomponent self-assembly: Supramolecular design of complex hydrogels for biomedical applications
Okesola, B. O., Redondo‐Gómez, C., & Mata, Á. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102015-9.00019-8 · Cited by 17
Intermittent supplementation with Akkermansia muciniphila and galactooligosaccharides modulates Alzheimer’s disease progression, gut microbiota, and colon short-chain fatty acid profiles in mice
Kunevičius, A., Vijaya, A. K., Atzeni, A., Mingaila, J., Šimoliūnė, I., Jamontas, R., Kezeviciute, E., Gueimonde, M., Meškys, R., Baltriukienė, D., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1617980 · Cited by 17
Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians
Kim, S., Nho, K. T., Ramanan, V. K., Lai, D., Foroud, T., Lane, K. A., Murrell, J. R., Gao, S., Hall, K. S., Unverzagt, F. W., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150651 · Cited by 16
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a trans-alkene spacer as potent GABA uptake inhibitors
Tóth, K., Höfner, G. C., & Wanner, K. T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.002 · Cited by 14
Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity
Zaręba, P., Sałat, K., Höfner, G. C., Łątka, K., Bajda, M., Latacz, G., Kotniewicz, K., Rapacz, A., Podkowa, A., Maj, M., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113512 · Cited by 14
The Effect of Gut Microbe Dysbiosis on the Pathogenesis of Alzheimer's Disease (AD) and Related Conditions
Nafady, M. H., Sayed, Z. S., Abdelkawy, D. A., Shebl, M. E., Elsayed, R. A., Ashraf, G. M., Perveen, A., Attia, M. S., & Bahbah, E. I. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220419101205 · Cited by 13
Exploring the Interactions Between Neurophysiology and Cognitive and Behavioral Changes Induced by a Non-pharmacological Treatment: A Network Approach
Rodríguez-González, V., Gómez, C., Hoshi, H., Shigihara, Y., Hornero, R., & Poza, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.696174 · Cited by 13
“Likewise, it has also been linked to neuroplasticity, as well as to behavioral and psychological symptoms of dementia via GABAergic activity (Lanctôt et al., 2004; Griffen and Maffei, 2014).”
Background
Electroacupuncture Ameliorates Cognitive Impairment by Regulating γ-Amino Butyric Acidergic Interneurons in the Hippocampus of 5 Familial Alzheimer’s Disease Mice
Li, H., Lai, L., Li, X., Wang, R., Fang, X., Xu, N., & Zhao, J. (2023) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2022.11.014 · Cited by 13
Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design
Herrmann, N. (2007) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100005667 · Cited by 13
Self-citation
Modulation of gut microbiota by dietary supplementation with tuna oil and algae oil alleviates the effects of D-galactose-induced ageing
Zhang, H., Li, Y., Cui, C., Sun, T., Han, J., Zhang, D., Lu, C., Zhou, J., Cheong, L., Li, Y., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8775-1 · Cited by 14
“…(Allen et al. 2011). γAminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system of humans, plays a vital role in anti-ageing effects, and dysfunction of the GABAergic system might lead to cognitive dysfunction (Barrett 2014; Hu et al. 2016; Lanctôt et al. 2004).”
Background
1H- and 13C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer’s disease
Doert, A., Pilatus, U., Zanella, F., Müller, W. E. G., & Eckert, G. P. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1387-3 · Cited by 14
Copper chloride dose-dependently alters spatial learning and memory, and glutamate levels, in the hippocampus of rats
Zhang, G., Li, Q., Gao, W., Liu, S., Wu, R., Shen, Z., Liu, W., & Chen, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8278 · Cited by 12
“GABA is a principal inhibitory neurotransmitter in the CNS and is known to be associated with cognitive function (39).”
Receptores neurais e a doença de Alzheimer: uma revisão sistemática da literatura sobre as famílias de receptores mais associadas a doença, suas funções e áreas de expressão
Câmara, A. B. (2019) · Jornal Brasileiro de Psiquiatria · doi:10.1590/0047-2085000000242 · Cited by 12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors
Tóth, K., Höfner, G. C., & Wanner, K. T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.049 · Cited by 12
Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics
Banerjee, A., Pradhan, L. K., Sahoo, P. K., Jena, K. K., Chauhan, N. R., Chauhan, S., & Das, S. K. (2021) · Archives of Microbiology · doi:10.1007/s00203-021-02276-9 · Cited by 13
In vitro differentiation of GABAergic cells from bone marrow stromal cells using Potassium Chloride as inducer
Gharibani, P. M., Tiraihi, T., & Arabkheradmand, J. (2010) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2010-0539 · Cited by 11
Control of N‐Heterocyclic Carbene Catalyzed Reactions of Enals: Asymmetric Synthesis of Oxindole‐γ‐Amino Acid Derivatives
Chen, X., Xiong, J., Liu, Q., Li, S., Sheng, H., von Eßen, C., Rissanen, K. T., & Enders, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201708994 · Cited by 11
N‐Substituted Nipecotic Acids as (S)‐SNAP‐5114 Analogues with Modified Lipophilic Domains
Böck, M. C., Höfner, G. C., & Wanner, K. T. (2020) · ChemMedChem · doi:10.1002/cmdc.201900719 · Cited by 10
Acute and chronic effects of intravitreally injected β-amyloid on the neurotransmitter system in the retina
Aruoma, O. I., Jen, S. S. M., Watts, H. R., George, J., Gentleman, S. M., Anderson, P. J., & Jen, L. (2008) · Toxicology · doi:10.1016/j.tox.2008.11.007 · Cited by 9
Clinical Update on Nursing Home Medicine: 2016
Messinger‐Rapport, B. J., Little, M. O., Morley, J. E., & Gammack, J. K. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.09.004 · Cited by 10
Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer’s Disease Therapy
Moreira, P., Matos, P., Figueirinha, A., Salgueiro, L., Batista, M. T., Branco, P. C., Cruz, M. T., & Pereira, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158812 · Cited by 10
“γ-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the human brain, which plays a relevant role in cognitive functions [250] (Figure 7A).”
Background
GAD65 as a potential marker for cognitive performance in an adult population with prediabetes
Tsai, C. K., Kao, T. W., Lee, J. T., Wang, C. C., Chou, C.-H., Liang, C., Yang, F. C., & Chen, W. (2019) · QJM · doi:10.1093/qjmed/hcz239 · Cited by 8
Decrease of GABAergic Markers and Arc Protein Expression in the Frontal Cortex by Intraventricular 192 IgG-Saporin
Jeong, D. U., Chang, W. S., Hwang, Y. S., Lee, D., & Chang, J. W. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330741 · Cited by 8
In vitro transdifferentiation of bone marrow stromal cells into GABAergic-like neurons.
Gharibani, P. M., Tiraihi, T., & Arabkheradmand, J. (2009) · PubMed · Cited by 8
Use of Drugs Affecting GABAA Receptors and the Risk of Developing Alzheimer’s Disease and Dementia: a Meta-Analysis and Literature Review
Vakili, K. G., Fathi, M., Ebrahimi, R., Ahmadian, S., Moafi, M., Ebrahimi, M. J., Tafazolimoghadam, A., Davoodi, A., Eghbaldoost, A., Eyvani, K., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04821-9 · Cited by 7
“Therefore, this system has become a target for understanding the pathophysiology of AD and for developing effective treatments [15].”
Molecular signatures of regional vulnerability to tauopathy in excitatory cortical neurons
Broekaart, D. W. M., Sharma, A., Ramakrishnan, A., Chongtham, A., Günther, D. M., Subramaniyan, S., Wang, M., Patel, V., Zhang, B., Grinberg, L. T., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02879-2 · Cited by 7
“Several studies have shown a dysfunctional inhibitory network in AD, with decreased expression of GABA in the neocortex and in cerebrospinal fluid, along with a loss of somatostatin-expressing interneurons [22, 32, 59, 80].”
Symptômes comportementaux et psychologiques lors de démence
Lebert, F., & Pasquier, F. (2008) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(08)48826-7 · Cited by 7
Effects of Dizocilpine, Midazolam and Their Co-Application on the Trimethyltin (TMT)-Induced Rat Model of Cognitive Deficit
Chvojková, M., Kubová, H., & Valeš, K. (2021) · Brain Sciences · doi:10.3390/brainsci11030400 · Cited by 7
“On the other hand, side effects may limit the use of these compounds [18].”
Background
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors
Tóth, K., Höfner, G. C., & Wanner, K. T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.024 · Cited by 7
Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets
Li, G., Li, F., Tang, Y., Guo, S., Yao, Y., Yuan, F., Zhang, B., Jiang, Y. Y., Wang, J., Wu, D., et al. (2025) · MedComm · doi:10.1002/mco2.70556 · Cited by 6
Antipsychotics in Alzheimer's disease: A critical analysis
da Silva, E. M., Braga, R. D. C. O. P., Avelino‐Silva, T. J., & Gil, L. A. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05010007 · Cited by 6
Molecular recognition of ω-amino acids by thiazolobenzocrown receptors: a GABA-selective ionophore
Yi, Y. R., Kim, K.-S., Helal, A., & Kim, H.-S. (2012) · Supramolecular chemistry · doi:10.1080/10610278.2012.726731 · Cited by 6
Diabetic Theory in Anti-Alzheimer’s Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors
Jankowska, A., Pawłowski, M., & Chłoń‐Rzepa, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200917125857 · Cited by 7
Vocally disruptive behavior: A case report and literature review
McCarthy, B., Boland, A. J., Murphy, S., & Cooney, C. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.18 · Cited by 5
“While the GABAminergic system has not specifically been associated with VDB, it has been linkedwith severe behavioral problems in dementia (Lanctôt et al., 2004).”
Background
Construction of 4-substituted 2-(pyrrolidine-3-yl)acetic acid derivatives as cyclic γ-aminobutyric acid analogues employing intermolecular [2+2]-photocycloaddition as key steps
Petz, S., Allmendinger, L., Mayer, P., & Wanner, K. T. (2019) · Tetrahedron · doi:10.1016/j.tet.2019.03.043 · Cited by 5
Microbiota-Gut-Brain Axis
Szablewski, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00065-6 · Cited by 5
Dysregulated Neurotransmitters and CB1 Receptor Dysfunction and Their Roles in Agitation Associated with Alzheimer’s Disease
Rao, J. S., Tangarife, M. A., Rodríguez‐Soacha, D. A., Arbelaez, M. J., Venegas, M. M., Delgado‐Murillo, L., Shahnawaz, S. S., Grimaldi, C., Gutiérrez, E., & Mukunda, R. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2020015 · Cited by 4
Interneurons in the CA1 stratum oriens expressing αTTP may play a role in the delayed-ageing Pol μ mouse model
Selva-Clemente, J., Marcos, P., González-Fuentes, J., Villaseca-González, N., Lagartos-Donate, M. J., Insausti, R., & Jiménez, M. D. M. A. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103960 · Cited by 3
Caffeine, vanillin and their combination modulate purinergic enzyme activities, mRNA expressions of some synapticsentry proteins and histomorphological status of hippocampal tissue in aluminum chloride-induced neurotoxicity in rats
Afolabi, O. B., Jaiyesimi, K. F., Olasehinde, O. R., Olaoye, O. A., Ekakitie, L. I., Adetunji, A. E., Fafure, A. A., Babatunde, O. J., & Oloyede, O. I. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100201 · Cited by 3
Synthesis and biological evaluation of α- and β-hydroxy substituted amino acid derivatives as potential mGAT1–4 inhibitors
Andreß, J. C., Böck, M. C., Höfner, G. C., & Wanner, K. T. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02548-x · Cited by 3
Agitation in Patients with Dementia - Challenges in Diagnosis and Treatment
Sommer, O. H. (2010) · NORA - Norwegian Open Research Archives · Cited by 3
Identification of Pyrrolidine‐3‐acetic Acid Derived Oximes as Potent Inhibitors of γ‐Aminobutyric Acid Transporter 1 through Library Screening with MS Binding Assays
Huber, S. K., Höfner, G. C., & Wanner, K. T. (2018) · ChemMedChem · doi:10.1002/cmdc.201800556 · Cited by 2
Describing Brain Activity of Persons With AD and Depressive Symptoms
Holston, E. C. (2014) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2014.09.002 · Cited by 2
Neurodegenerative Diseases and the Gut Microbiota
Cabré, S., O’Riordan, K. J., & Cryan, J. F. (2022) · Progress in inflammation research · doi:10.1007/978-3-030-91051-8_11 · Cited by 2
阿尔茨海默病与肠道微生物
胡, 旭., 金, 锋., & 王, 涛. (2016) · Scientia Sinica Vitae · doi:10.1360/n052016-0080 · Cited by 1
Functional and structural brain markers of Alzheimer’s disease : clinical studies using EEG and VBM
van Deursen, J. A. (2009) · Research Publications (Maastricht University) · doi:10.26481/dis.20090409jd · Cited by 2
Emerging approaches for the treatment of Alzheimer disease: Targeting NF-κB pathwayPreprint
Goel, A. S., & Singh, S. (2020) · doi:10.22541/au.159493419.94920936 · Cited by 2
Modulation of ion channels in clinical psychopharmacology: adults and younger people
Sinclair, L. I., Dineen, P., & Malizia, A. L. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.21 · Cited by 1
Antipsychotics in Alzheimer's disease
da Silva, E. M., Oliveira, C., Braga, P., Avelino‐Silva, T. J., & Gil, L. A. (2011) · Cited by 1
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with tricyclic cage structures in the lipophilic domain as GABA uptake inhibitors
Rudy, H. A., Höfner, G. C., & Wanner, K. T. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02647-9 · Cited by 1
Effect of Methylphenidate on Attention in Apathetic Alzheimer’s Disease Patients and Association with Apathy Changes in a Randomized, Placebo-controlled Trial
Chau, S. A. (2013) · TSpace (University of Toronto)
Gut Microbiota, Formaldehyde Dysmetabolism, and Cognitive Impairment
Liu, K., & He, R. (2017) · Springer eBooks · doi:10.1007/978-94-024-1177-5_6
Biochemistry and Neuropharmacology
Avari, J., Goettsche, K. R., & Snow, C. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-73078-3_7
Neuro-inflammation dans les maladies neurologiques. Rôle des probiotiques
Joffre, C., Dinel, A., & Layé, S. (2018) · Phytothérapie · doi:10.3166/phyto-2018-0093
Screening and evaluation of natural compounds for therapeutic application in Alzheimer's disease
Nirvanashetty, S. (2024) · Swinburne figshare (Swinburne University of Technology) · doi:10.25916/sut.26278636
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1)
Huber, S. K., Höfner, G. C., & Wanner, K. T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.001
The role of APP and its homologous proteins in synaptic function and plasticity
Kilian, B. S. (2008) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-200906220200-9
Modulation of Gut Microbiota through Mediterranean Diet as a New Insight for the Alzheimer's Disease Therapy
Fahira, A., Widjaja, H. T., & Aditya, N. (2019) · Journal of Asian Medical Students Association
Gut Microbiota in Brain diseases
Salami, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00040-1
Effect Of A Lactobacilli Probiotic On Longevity And Mobility Of Male Drosophila Melanogaster With Alzheimer’s Disease
Lim, C. P. (2020) · Universiti Sains Malaysia Institutional Repository (Universiti Sains Malaysia)
Triptolide Reduced Alzheimer's Disease-Like Presentation in MicePreprint
Mao, R., Xu, S., Sun, G., Yu, Y., Zuo, Z., Wang, Y., Yang, K. Y., Zhang, Z., & Yang, W. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3981437
Anticonvulsants
Murphy, M. P. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_1627
Anticonvulsants
Murphy, M. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_1627
Anticonvulsants
Murphy, M. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-56782-2_1627-2
Anxiolytics
Kolakowsky‐Hayner, S. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_1757
Anxiolytics
Creque, C., & Kolakowsky‐Hayner, S. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56782-2_1757-2
Anxiolytics
Creque, C., & Kolakowsky‐Hayner, S. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_1757
Neuropharmacology in Alzheimer and Huntington Disease
Gupta, B., & Rohatgi, K. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815040913122010015
Research progress in relationship between gut microbiota and Alzheimer’s disease
Li, D., Li, Y., & Zhang, Z. (2023) · International Conference on Modern Medicine and Global Health (ICMMGH) · doi:10.1117/12.2691850
“Lactobacillus and Bifidobacterium from human intestines increase GABA levels, and probiotic mixtures can improve cognitive ability in AD patients [18].”
Background
Neuromodulatory effects of caffeine, vanillin and their combination via the assessment of hippocampal purinergic enzymes and expressions of cholinergic, eNOS, GABA receptor, amyloid protein and histomorphological status of AlCl3-induced Alzheimer’s disease in adult male Wistar ratsPreprint
Afolabi, O. B., Jaiyesimi, K. F., Olasehinde, O. R., Olaoye, O. A., Ekakitie, L. I., Fafure, A. A., Adetunji, A. E., Oluwafemi, E. B., & Oloyede, O. I. (2023) · Research Square · doi:10.21203/rs.3.rs-3433636/v1
From local activation to global synchronisation: Methodological challenges of M/EEG analysis for biomedical applications
González, V. R. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/68932
Gut Microbiota, Formaldehyde Dysmetabolism, and Cognitive Impairment
Liu, K., He, Y., Wen, B., Yan, W., & He, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-7281-3_7
Multicomponent synthesis and pharmacological evaluation of multi-targeted directed Ligand via Ugi and Hantzsch reactions as a solution for Alzheimer's disease.
Pachón-Angona, I. (2019) · theses.fr (ABES) · doi:10.70675/180e26f9z2aa3z4b87zabc0zf94e77b0b48d
BindingDB Entry 50041954: Aminomethyltetrazoles as potential inhibitors of the¿-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
BindingDB (2013) · UC San Diego · doi:10.7270/q2154jb8
BindingDB Entry 50001313: Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
BindingDB (2020) · UC San Diego · doi:10.7270/q20004mb
BindingDB Entry 50009599: Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q28k7djr
BindingDB Entry 50014523: Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
BindingDB (2022) · UC San Diego · doi:10.7270/q2r21568
BindingDB Entry 50045457: Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
BindingDB (2016) · UC San Diego · doi:10.7270/q2qr4ztk
BindingDB Entry 50007571: Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
BindingDB (2021) · UC San Diego · doi:10.7270/q2kd227r
BindingDB Entry 50003086: Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a trans-alkene spacer as potent GABA uptake inhibitors.
BindingDB (2020) · UC San Diego · doi:10.7270/q28k7csg
BindingDB Entry 50047225: Synthesis of 4-substituted nipecotic acid derivatives and their evaluation as potential GABA uptake inhibitors.
BindingDB (2017) · UC San Diego · doi:10.7270/q2df6t3c

Authors: Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N.
Affiliations: Sunnybrook Health Science Centre (CA)
Corresponding author: Lanctôt, Krista L
ORCID: Lanctôt, Krista L
Herrmann, Nathan
Venue: The Canadian Journal of Psychiatry
Publisher: SAGE Publications
Published: 2004-07
Volume: 49
Issue: 7
Pages: 439-453
ISSN: 0706-7437 (ISSN-L)
1497-0015
DOI: 10.1177/070674370404900705
OpenAlex: W2184602814
Cited by: 191
References: 146
Citations by year: 2025: 7 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 12 · 2019: 13 · 2018: 19 · 2017: 15 · 2016: 11 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 6
FWCI: 3.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: The Canadian Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Society
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: Alzheimer's disease, GABA, GABAergic dysfunction, behavioral and psychological symptoms of dementia, inhibitory neurotransmitter, GABAergic drugs, anxiolytics, antiepileptic drugs, disease subtypes
MeSH terms: Aged, Alzheimer Disease, Benzodiazepines, Binding Sites, Brain, Frontal Lobe, gamma-Aminobutyric Acid, Humans, Limbic System, Parietal Lobe, Temporal Lobe, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Receptors, GABA, GABA Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks